Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Cipla forms alliance with Serum Institute to market paediatric vaccines in Europe

While Serum Institute will manufacture paediatric vaccines, Cipla will seek approvals and market the products in Europe

BS B2B Bureau  |  Mumbai 

Venturing into the segment, Cipla, through its subsidiary Europe NV, has entered into an agreement to distribute of India Ltd’s (SII) paediatric in Europe. As per the agreement, of India, a Poonawalla group company and one of the leading manufacturers of in India, will develop and manufacture paediatric vaccines, while will seek approval and market the products in Europe. The will be manufactured in Serum’s production facilities approved by WHO.
 
Subhanu Saxena, MD & Global CEO, Limited, said, “We are proud to have entered into a strategic Europe-specific partnership with of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both and share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases.”


 
Adar Poonawalla, CEO and Executive Director, SII, added, “believes that this tie-up with is a perfect platform for making available for Europeans as Serum also shares the common philosophy of of making vaccines/pharmaceutical products available at the most affordable prices. Therefore as the two companies are aligned in many ways, we feel this will be a good partnership.”
 
According to Frank Pieters, Head of Europe, Cipla, the company sees as one of the critical components of its offering to European patients. “With Cipla’s front-end presence and with the support of a dedicated sales force, we will broaden the reach of across Europe,” he added.
 
Over the last 6 months, has strengthened its foundation in Europe. The company has launched respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia. In July, has signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusORTM in regional anesthetic applications for post-surgical pain management.

RECOMMENDED FOR YOU

Cipla forms alliance with Serum Institute to market paediatric vaccines in Europe

While Serum Institute will manufacture paediatric vaccines, Cipla will seek approvals and market the products in Europe

While Serum Institute will manufacture paediatric vaccines, Cipla will seek approvals and market the products in Europe Venturing into the segment, Cipla, through its subsidiary Europe NV, has entered into an agreement to distribute of India Ltd’s (SII) paediatric in Europe. As per the agreement, of India, a Poonawalla group company and one of the leading manufacturers of in India, will develop and manufacture paediatric vaccines, while will seek approval and market the products in Europe. The will be manufactured in Serum’s production facilities approved by WHO.
 
Subhanu Saxena, MD & Global CEO, Limited, said, “We are proud to have entered into a strategic Europe-specific partnership with of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both and share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases.”
 
Adar Poonawalla, CEO and Executive Director, SII, added, “believes that this tie-up with is a perfect platform for making available for Europeans as Serum also shares the common philosophy of of making vaccines/pharmaceutical products available at the most affordable prices. Therefore as the two companies are aligned in many ways, we feel this will be a good partnership.”
 
According to Frank Pieters, Head of Europe, Cipla, the company sees as one of the critical components of its offering to European patients. “With Cipla’s front-end presence and with the support of a dedicated sales force, we will broaden the reach of across Europe,” he added.
 
Over the last 6 months, has strengthened its foundation in Europe. The company has launched respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia. In July, has signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusORTM in regional anesthetic applications for post-surgical pain management.
image
Business Standard
177 22

Cipla forms alliance with Serum Institute to market paediatric vaccines in Europe

While Serum Institute will manufacture paediatric vaccines, Cipla will seek approvals and market the products in Europe

Venturing into the segment, Cipla, through its subsidiary Europe NV, has entered into an agreement to distribute of India Ltd’s (SII) paediatric in Europe. As per the agreement, of India, a Poonawalla group company and one of the leading manufacturers of in India, will develop and manufacture paediatric vaccines, while will seek approval and market the products in Europe. The will be manufactured in Serum’s production facilities approved by WHO.
 
Subhanu Saxena, MD & Global CEO, Limited, said, “We are proud to have entered into a strategic Europe-specific partnership with of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both and share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases.”
 
Adar Poonawalla, CEO and Executive Director, SII, added, “believes that this tie-up with is a perfect platform for making available for Europeans as Serum also shares the common philosophy of of making vaccines/pharmaceutical products available at the most affordable prices. Therefore as the two companies are aligned in many ways, we feel this will be a good partnership.”
 
According to Frank Pieters, Head of Europe, Cipla, the company sees as one of the critical components of its offering to European patients. “With Cipla’s front-end presence and with the support of a dedicated sales force, we will broaden the reach of across Europe,” he added.
 
Over the last 6 months, has strengthened its foundation in Europe. The company has launched respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia. In July, has signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusORTM in regional anesthetic applications for post-surgical pain management.

image
Business Standard
177 22